Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic industry players support the regional Medicare contractor’s evidence-based reimbursement requirements for molecular diagnostics and are hoping CMS adopts the approach nationally.